Nocion Therapeutics, Inc., a biopharmaceutical company developing novel small molecule charged sodium channel blockers, has dosed the first patient with NOC-100, an inhaled formula of its NTX-1175 small molecule candidate. NTX-1175 is being developed to treat cough and has received priority review through the U.K.’s Medicines and Healthcare products Regulatory Agency, as NOC-100 has the potential to treat both chronic and acute cough – the latter a common symptom in patients with COVID-19 an...